Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Zynerba Pharmaceuticals (ZYNE) Stock Price
Media stories about Zynerba Pharmaceuticals (NASDAQ:ZYNE) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Zynerba Pharmaceuticals earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave news coverage about the company an impact score of 44.967852318068 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) traded down 1.73% during trading on Wednesday, hitting $6.24. The company had a trading volume of 199,481 shares. Zynerba Pharmaceuticals has a 12-month low of $6.10 and a 12-month high of $23.57. The firm has a 50 day moving average of $6.28 and a 200 day moving average of $17.73. The stock’s market cap is $82.72 million.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its quarterly earnings data on Tuesday, August 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.04). On average, analysts forecast that Zynerba Pharmaceuticals will post ($2.42) earnings per share for the current fiscal year.
Several equities analysts have recently issued reports on the company. Maxim Group set a $32.00 price target on Zynerba Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, June 26th. Zacks Investment Research upgraded Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 13th. BidaskClub upgraded Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. Cantor Fitzgerald set a $28.00 price target on Zynerba Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, June 8th. Finally, Roth Capital set a $30.00 price target on Zynerba Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, June 10th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $12.67.
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.